89 results about "Low toxicity" patented technology

The invention discloses application of pseudo-ginseng external vesicles in preparation of drugs for preventing and treating or improving heart diseases. The plant exovesicle provided by the invention has the advantages of low toxicity, high biocompatibility, biodegradability, no induction of immunogenicity, high yield and large-scale preparation. A large number of experimental studies prove that the pseudo-ginseng external vesicles disclosed by the invention have a remarkable heart disease prevention and treatment effect. Therefore, development and application of the fresh pseudo-ginseng medicine are promoted.

The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. The composition has considerable curative effects on fungal infections on the skin surfaces of animals, with low toxicity and minimal irritation.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

The invention relates to the technical field of medicines, and particularly discloses application of a Xinjiang medicine mulberry extract in preparation of a medicine for treating or preventing periapical periodontitis, which is technically characterized in that the Xinjiang medicine mulberry extract is found and proved to have a remarkable inhibition effect on periapical periodontitis key pathogenic bacterium enterococcus faecalis for the first time, the minimum inhibitory concentration (MIC) is 0.604 mg / mL, and the Xinjiang medicine mulberry extract has a remarkable inhibition effect on the periapical periodontitis key pathogenic bacterium enterococcus faecalis. The minimum bactericidal concentration (MBC) is 1.875 mg / mL, and a biological membrane can be effectively inhibited and removed; in-vivo experiments of a rat periapical periodontitis model prove that the extract can remarkably reduce the number of bacteria in root canals and relieve periapical bone destruction, the curative effect is equivalent to that of calcium hydroxide, and the extract is non-toxic to main organs and high in biocompatibility. The invention provides a new candidate and a clear technical scheme for developing an efficient and low-toxicity natural plant source root canal disinfectant.

This invention provides a drug-coated balloon catheter, its preparation method, and its application, relating to the field of medical device technology. The drug-coated balloon catheter includes a balloon catheter and a drug coating disposed on the surface of the balloon catheter; the drug coating includes an active drug and an excipient; the active drug is a flavonoid. The drug-coated balloon catheter utilizes flavonoids, which combine the advantages of low toxicity and high water solubility. While reducing the toxic side effects of the drug coating, it achieves rapid release and efficient absorption of the drug. Furthermore, through a dual mechanism of anti-proliferation and anti-inflammation, it effectively solves the problems of potential toxic side effects, limited transport efficiency, and limited functionality that may exist in existing products at high dose densities.

A benzofuran-based N-acylhydrazone derivative according to the present invention has an excellent anticancer effect while having low toxicity and excellent solubility, and thus a pharmaceutical composition comprising the derivative can be usefully used to prevent or treat a cell proliferative disorder including various cancers.

The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.

The invention discloses an electrochemical polishing solution for laser additive manufacturing of a tantalum material and a preparation method and process, and relates to the technical field of surface treatment of metal workpieces. According to the electrochemical polishing solution, an alcohol-salt system is adopted for electropolishing treatment, and compared with a traditional electropolishing solution, the electrochemical polishing solution has the advantages of electrochemical and chemical stability, relatively high conductivity, relatively high controllability, relatively low toxicity, low volatility, environment friendliness and the like; the electropolishing solution has the characteristics of no volatilization, no odor, low toxicity to a human body and the like by adding the inorganic solid acid formed by replacing sulfamic acid sulfuric acid hydroxyl with amino, and not only has the oxidation capacity of sulfuric acid, but also can promote dissolution and improve the material removal rate by the amino; the electrochemical polishing solution is mild in process parameter, insensitive to temperature, capable of implementing polishing at room temperature, small in corrosion to electrolysis equipment and capable of being used for a long time.

This invention belongs to the field of chemical pharmaceuticals, specifically relating to a thiazole compound, its preparation method, pharmaceutical composition, and uses. The structure of this thiazole compound is shown in Formula I, wherein R1 and R2 are independently selected from one of the following: hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl. The thiazole compound proposed in this invention can inhibit LSD1 protease activity and simultaneously possesses low toxicity, high efficiency, high selectivity, and minimal off-target effects.

This invention belongs to the field of biotechnology and pharmaceutical technology, and discloses an ACLY-targeting PROTAC chimera with anti-MASH activity using a glycol chain as the linking chain. Its general structural formula is Formula 1: R is -(CH2-O-CH2). n -, n is 2-6. The PROTAC compound synthesized in this invention is a novel compound. In a high-fat model established using L02 and HepG2 cells, the synthesized PROTAC compound exhibits activity in reducing TG content. Compared with the warhead, the synthesized PROTAC compound shows low toxicity activity in human hepatocellular carcinoma cells HepG2, normal human hepatocytes L02, and human umbilical vein endothelial cells HUVEC, making it a novel, low-toxicity, and highly effective drug for treating non-alcoholic steatohepatitis (NAH). This invention expands the application areas of PROTAC technology while developing a highly effective treatment for NHA.

The application belongs to the technical field of biology and medicine, and discloses a PROTAC compound with a carbon chain as a connecting chain, which is developed based on a PROTAC technology, and a structural general formula of the PROTAC compound is formula 1: wherein R is -(CH2) n -, and n is 3-8. The synthesized PROTAC compound is a new compound, has a TG content reducing activity in a high-fat model established by L02 and HepG2, and has a low-toxicity activity in human hepatoma cells HepG2, human normal liver cells L02 and human umbilical vein endothelial cells HUVEC compared with a warhead. The synthesized PROTAC compound is a new type of anti-non-alcoholic fatty liver disease drug with low toxicity and high efficiency. The application of the PROTAC technology is widened while developing an efficient treatment of anti-non-alcoholic fatty liver disease.

The invention discloses an anti-cancer oligopeptide designed based on threonine and analogues thereof and application of the anti-cancer oligopeptide, the anti-cancer oligopeptide is obtained by taking KLLKKLLKKLLKKKLLKW as a structural basis, replacing amino acids at different sites with hydroxyl-containing threonine or analogues thereof, and then amidating a C terminal; the structural general formula of the compound is as follows: KXmLKKLLKKLLKW-NH2, wherein X = T, pT, F, Y or pY, and p represents phosphorylation; and m is 2, 3, 6, 7, 10, 11 or 13. The anti-cancer oligopeptide has the advantages of high efficiency, low toxicity, short sequence and the like. In-vitro anti-tumor activity and toxicity experiment results show that the compound has a relatively strong killing effect on various tumor cells, and is low in hemolytic toxicity and high in therapeutic index. Serum stability experiments further show that the protein has relatively high enzymolysis stability. A scanning electron microscope experiment shows that the anti-cancer oligopeptide can quickly kill tumor cells through an effective membrane rupture mechanism. Therefore, the compound has a good application prospect in the aspects of research on novel high-efficiency low-toxicity polypeptide anti-cancer drugs, resistance to multidrug resistance and preparation of anti-cancer drugs.

The application relates to application of a piezoelectric material in preparation of a medicine for treating gout, characterized in that a medicine active ingredient of the medicine comprises the piezoelectric material, the piezoelectric material is barium titanate; the application comprises the following steps: delivering the medicine to a lesion site, applying ultrasonic stimulation to the lesion site, and exciting in-vivo active species degradation of uric acid by the medicine. The piezoelectric material has good piezoelectric catalytic performance, excellent tissue penetration ability, low toxicity and high precision, active species can be controllably excited by means of ultrasonic action at the time of gout attack, uric acid can be efficiently degraded into allantoin which is good in solubility and non-toxic, symptoms can be rapidly relieved, the piezoelectric material can be long-term resident in joints, can keep stable catalytic effect in multiple cycles, and long-term treatment of gout can be realized by single injection, and a new gout treatment scheme which is more effective and more durable is provided.

According to the application of the implant-derived exosome as the carrier in preparation of the medicine for targeted therapy of colitis, chicoric acid is loaded in the purple rice exosome, so that the defects that chicoric acid is low in oral bioavailability and poor in gastrointestinal tract stability are overcome, colon targeting and accumulation of the medicine are achieved, and the curative effect of the medicine is improved. An ideal functional carrier and a candidate preparation are provided for developing a novel anti-colitis nano-drug with high efficiency and low toxicity, and an innovative path is opened up for deep processing and industrial chain extension of purple rice resources in Yunnan province.

The present application belongs to the field of medical material surface functionalization, and particularly relates to a kind of nano drug-loaded hydrogel catheter coating and its preparation method and application.The present application utilizes PLGA to load antibiotic amikacin sulfate AMK or antibacterial peptide FK13-a1, synthesizes nanoparticle NP-AM and nanoparticle NP-FK, prepares NP-AM / FK@OMV nanoparticle complex with EcN OMV as carrier, then adds poloxamer-hyaluronic acid composite hydrogel to obtain NP-AM / FK@OMV-P / H nano drug-loaded hydrogel, and forms coating after coating and drying.The nano drug-loaded hydrogel coating provided by the present application has the characteristics of enzyme response, antibacterial, prevention of biofilm formation and low toxicity, has great application potential in inhibiting medical catheter surface biofilm, and has important significance for preventing and treating CAUTI, prolonging the use time of indwelling catheter, and reducing the discomfort of patients caused by frequent replacement of catheter.

This invention relates to deuterated 3-oxo-2,3-dihydropyridazine-4-carboxamide inhibitors, their preparation methods, and applications. Specifically, the compounds of this invention have the structure shown in formula (I). This invention also discloses the preparation method of the compounds and their use as AhR inhibitors. The compounds of this invention exhibit excellent selective inhibition of AhR and possess better pharmacodynamic and pharmacokinetic properties, as well as lower toxicity.

The present application provides a milbemycin oxime praziquantel-based parasitic expelling drug, which comprises the following components in parts by mass: modified milbemycin oxime 10-30 parts, nano-coated praziquantel 20-50 parts, compound synergist 5-15 parts, flavoring agent 3-8 parts, and disintegrating agent 2-5 parts. The application of the milbemycin oxime praziquantel-based parasitic expelling drug is used for preparing a preparation for preventing or treating mixed parasitic infection of dogs and cats, wherein the parasites include tapeworms, nematodes, trematodes and Demodex. Through the integrated innovation of chemical modification (succinylated milbemycin oxime), nanotechnology (HPMC-coated praziquantel) and compound synergy (non-ban Tai'er-beta cyclodextrin), the comprehensive advantages of broad-spectrum parasitic expelling, long-acting stability, safety and low toxicity are realized, and the pain points such as poor palatability, high metabolic burden and weak environmental adaptability in the prior art are solved, and the application is suitable for the prevention and treatment of mixed parasitic infection of dogs and cats.

The invention relates to a TCEP-based recombinant proinsulin inclusion body denaturation and renaturation method, according to the method, TCEP is added as a reducing agent in the denaturation and renaturation process, compared with the prior art, the yield of proinsulin denaturation and renaturation is increased, and the yield of insulin is remarkably increased. Besides, TCEP is high in reducibility, wide in applicable pH range and extremely low in toxicity, so that the production efficiency and the process stability of the recombinant insulin production process can be remarkably improved, the harm to operators and the environment is reduced, and the requirements of green chemistry and safe production are met.

The invention discloses an application of an AC13 compound or a pharmaceutical salt thereof in preparation of a medicine for treating enteritis. The structure of the AC13 compound is shown in the specification. The AC13 compound disclosed by the invention has a remarkable treatment effect on enteritis as a small molecule compound, and has the characteristics of low toxicity and remarkable curative effect. Therefore, the AC13 compound can be used as a lead compound of the major disease enteritis, has important development prospects and clinical application values, and also provides a scientific basis for further exploring the enteritis pathogenesis mechanism.

The present technology is directed to compounds Formulas I, II, III, and IV as well as compositions that include one or more of the compounds and methods of making the compounds. In particular, the present compounds may be used as a replacement for NMP in compositions to produce lower toxicity compositions.

This invention belongs to the field of biomedical technology, specifically relating to triptolide liposomes (TP-lipo), their combined use, and their application in the prevention and treatment of tumors. To enhance the efficacy of triptolide in the treatment and prevention of tumors such as pancreatic cancer, cervical cancer, ovarian cancer, and colorectal cancer, and to improve its bioavailability and clinical application while reducing toxicity, this invention uses HSPC, DOPS, and cholesterol as liposome components to encapsulate triptolide monomers, thus preparing TP-lipo. Experiments have shown that TP-lipo exhibits anti-tumor activity: it directly kills tumor cells and reverses the immunosuppressive microenvironment, making it a potential drug for tumor treatment. TP-lipo, when used in combination with PD-1 antibodies, or in combination with radiotherapy, chemotherapy, or surgery, demonstrates a potent and synergistic anti-tumor effect with low toxicity. Therefore, the TP-lipo of this invention provides more clinical strategies for tumor treatment.

The application discloses application of a Chinese medicine pair effective component composition of Astragalus membranaceus and Curcuma zedoary in preparation of anti-tumor metastasis drugs. The composition is composed of calycosin-7-glucoside and curcumin. The composition can effectively inhibit transendothelial invasion and vasculogenic mimicry generation of tumor cells at a non-toxic dose, and has the advantages of high efficiency and low toxicity in treating tumor metastasis. The important point of the application is that the preferred composition can significantly reduce the exosome LAP-TGF-beta1 protein loading level, thereby greatly inhibiting the tumor metastasis process caused by the exosome-mediated TGF-beta signal pathway. The finding provides a new perspective for the development of drugs for targeting exosome LAP-TGF-beta1 protein loading to resist tumor metastasis, and overcomes the defects of unclear effective components, uncontrollable proportioning and unclear treatment effect of traditional Chinese medicine compatibility. Therefore, the Chinese medicine effective component composition has application prospects in preparation of anti-tumor metastasis drugs.

The application provides application of alnus ketone in preparation of a medicine for preventing and / or treating ulcerative colitis, and belongs to the technical field of traditional Chinese medicines. The application research finds that alnus ketone can significantly reduce secretion of intestinal epithelial cell inflammatory factor IL-8, and has an anti-inflammatory effect. Animal experiments show that alnus ketone can reduce weight loss of mice caused by ulcerative colitis, reduce severity of occult blood, and reduce shortening of the colon, indicating that alnus ketone has a protective effect on ulcerative colitis. The alnus ketone is applied to clinical treatment, and has the advantages of high efficiency, low toxicity, economy and feasibility.

The application belongs to the technical field of chemical medicine, and particularly relates to a kind of 2,3-dihydropyrimidino [4,5-d] pyrimidine-4 (1H) -ketone derivatives and preparation method and purposes thereof.The existing Wee1 small molecule inhibitors still have one or more defects in activity, safety or pharmacokinetic properties, and a new generation of Wee1 small molecule inhibitors with novel structure, low toxicity, high efficiency and excellent pharmacokinetic properties needs to be developed.The application provides a kind of 2,3-dihydropyrimidino [4,5-d] pyrimidine-4 (1H) -ketone derivatives, specifically including 95 new compounds, or pharmaceutically acceptable salt thereof, or stereoisomer thereof.Experiments show that the compound of formula (I) disclosed in the application has good inhibitory activity on Wee1, and therefore the compound of the application can be used for treating diseases caused by abnormal Wee1 activity.

An application of a Bacillus Calmette-Guérin (BCG)-based outer membrane vesicle (OMV) trained immunity inducer in preparation of an immunotherapeutic drug for sepsis is provided. The disclosure isolates and collects OMVs secreted by BCG bacteria to obtain a BCG-based OMV trained immunity inducer (designated as B-OMVs). The B-OMVs combines distinct advantages of both BCG and OMVs while circumventing their respective drawbacks. The developed B-OMVs exhibits characteristics such as being non-replicative, non-infectious, and of low toxicity, resulting in minimal impact on the organism and high safety. In addition, the B-OMVs demonstrates a more moderate yet effective immunomodulatory capacity. It can induce trained immunity, enhance the body's resistance to microbial infections, reduce the need for antibiotics, and more effectively improve the prognosis of sepsis.

The invention discloses application of diterpenoid compounds in Physalis alkekengi in kidney diseases, and belongs to the technical field of medicines.The diterpenoid compound taepeenin D is obtained by being separated from Physalis alkekengi which is a Dai nationality medicine and food homologous plant, has a good anti-inflammatory effect, can inhibit expression of kidney inflammatory factors, is a natural extract and is free of toxic and side effects. The traditional Chinese medicine composition has the advantages of remarkable curative effect and low toxic and side effects, can be used for preparing medicines for treating kidney diseases and is expected to be applied to the fields of medicines, health-care products, cosmetics and the like.

[Object] The present application aims to provide an ornithine assembly having low toxicity, effects even when administered orally, and high bioavailability. In addition, the present application aims to provide an ornithine assembly effective for the prevention or treatment of liver damage. [Solution] A condensate in which an acyl group or the like is introduced into the ornithine side chain amino group of polyethylene glycol-b-polyornithine is provided, and further, a new assembly independent of PIC is provided.

The application discloses a Pickering emulsion based on extract of Herba Rehmanniae and a preparation method thereof. The Pickering emulsion only uses the extract of Herba Rehmanniae as a stabilizer, and does not need to add emulsifiers, surfactants and other modifiers. The Pickering emulsion preparation method comprises the following steps: preparing the extract of Herba Rehmanniae by using a pressurized hot water method; and mixing the extract aqueous solution with an oil phase, and then performing heating and stirring treatment to obtain the Pickering emulsion. The Pickering emulsion has the advantages of good biocompatibility, biodegradability and low toxicity, and can be used as a delivery system in the food, medicine and cosmetic industries, can load fat-soluble functional components, and can realize multiple utilities. The preparation method of the emulsion is simple, the operation conditions are mild and controllable, and industrialized production popularization can be easily realized.

The invention discloses a THPC cross-linked heart valve and a preparation method thereof. The preparation method of the THPC cross-linked heart valve comprises the following steps: performing decellularization treatment on biological tissues; soaking the biological tissue subjected to the decellularization treatment in a THPC cross-linking solution, and carrying out a cross-linking reaction; and after a preset time period, a reducing agent is adopted to terminate the cross-linking reaction and wash the biological tissue, and the THPC cross-linked heart valve is obtained. Through the mode, the preparation method of the THPC cross-linked heart valve, provided by the invention, can be used for preparing the THPC cross-linked heart valve under a mild reaction condition, so that the original characteristics of biological tissues can be reserved to the greatest extent, and various mechanical properties of the biological tissues can be improved; and the low toxicity of THPC ensures that the cross-linked material does not cause serious cytotoxic reaction and immunoreaction in the process of implanting into a human body or contacting with human tissues, so that the adhesion, proliferation and differentiation of cells on the surface of the material are facilitated, the repair and regeneration of tissues are promoted, and the safety and effectiveness of biomedical products are ensured.

This invention discloses the application of L-galactose in the preparation of drugs for the prevention and / or treatment of hyperuricemia-related diseases, as well as the use of L-galactose in preventive and therapeutic drugs. This invention is the first to discover and confirm that L-galactose has the activity of lowering uric acid levels in the body, representing a pioneering discovery of a new use for a known substance. It is anticipated that the use of L-galactose to treat hyperuricemia will have good biocompatibility, low toxicity, and high safety, making it particularly suitable as a therapeutic drug or daily health care ingredient for chronic diseases requiring long-term use (such as hyperuricemia and gout).